Januvia and sitagliptin: dose, kidney function and side effects
Januvia contains sitagliptin, a medicine from the group of DPP-4 inhibitors, sometimes called gliptins. It is used in adults with type 2 diabetes to improve blood sugar control, on its own when metformin is unsuitable or together with other diabetes medicines. This page sets out the dose in the product information, why your kidney function changes it, the warning signs that need medical help and how a request for sitagliptin is assessed.
What Januvia contains and how it is authorised
Each Januvia film-coated tablet contains sitagliptin, a medicine taken by mouth from the group of dipeptidyl peptidase-4 (DPP-4) inhibitors. It is not insulin and it is not injected. Januvia is authorised for the whole European Union through the central procedure, so its summary of product characteristics (SmPC) and package leaflet are published by the European Medicines Agency (EMA). Annex II of that product information classifies Januvia as a medicinal product subject to medical prescription.
Sitagliptin is also authorised nationally under other names. In the Medicines Authority register, 51 authorised products contain sitagliptin as the only active substance and 39 contain it together with another substance, such as metformin; every one of them is classified as a prescription-only medicine (POM). Janumet, which combines sitagliptin with metformin, is another centrally authorised product.
If you already take a combination tablet, adding plain sitagliptin would mean taking the same substance twice. Check the composition printed on each pack rather than the name, and ask the pharmacist when two packs look unfamiliar.
What sitagliptin is used for
The SmPC limits Januvia to adults with type 2 diabetes, in whom it is used to improve glycaemic control (section 4.1). It can be taken on its own when diet and exercise are not enough and metformin is unsuitable because of a contraindication or intolerance. It can also be added to other diabetes medicines when the treatment you already take does not control your blood sugar well enough. The table sums up the uses listed in the SmPC.
Which medicine is added, and in what order, is the doctor's decision, based on your results, your kidney function and your other conditions. Januvia does not replace diet and exercise: the leaflet asks you to stay on the diet and exercise your doctor has recommended while you take it. It is not used for type 1 diabetes or for diabetic ketoacidosis (SmPC, section 4.4). Our page on type 2 diabetes and blood sugar medicines compares the groups of medicines.
| Use in the SmPC | When it applies |
|---|---|
| Sitagliptin alone | Diet and exercise are not enough, and metformin is unsuitable because of a contraindication or intolerance |
| Added to metformin | Diet, exercise and metformin alone do not control blood sugar |
| Added to a sulphonylurea | The maximal tolerated sulphonylurea dose is not enough, and metformin is unsuitable |
| Added to a thiazolidinedione (PPAR-gamma agonist) | A PPAR-gamma agonist is appropriate but not enough on its own |
| Added to a sulphonylurea and metformin, or to a PPAR-gamma agonist and metformin | Dual therapy with these medicines is not enough |
| Added to insulin, with or without metformin | A stable insulin dose is not enough |
How sitagliptin lowers blood sugar
After a meal, the gut releases incretin hormones, including glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). When blood sugar is normal or raised, these hormones increase the release of insulin from the pancreas, and GLP-1 also lowers the release of glucagon, a hormone that raises blood sugar. The enzyme DPP-4 breaks the incretins down quickly.
Sitagliptin blocks DPP-4, so more of the active incretins stay in the blood. According to the SmPC (section 5.1), this raises insulin and lowers glucagon in a glucose-dependent way, which in people with type 2 diabetes lowers HbA1c and blood sugar both fasting and after meals. When blood sugar is low, this effect is not seen. The SmPC contrasts this with sulphonylureas, which increase insulin release even when glucose is low.
In the clinical studies described in section 5.1, body weight did not increase with sitagliptin taken on its own. Added to metformin, a PPAR-gamma agonist or insulin, the change in weight was similar to placebo, while added to glimepiride there was a modest increase compared with placebo. About 79% of a dose leaves the body unchanged in the urine (section 5.2), which is why kidney function sets the dose.
Doses in the summary of product characteristics
The dose in the SmPC is 100 mg of sitagliptin once a day (section 4.2), and the tablet can be taken with or without food. When Januvia is added to metformin or a PPAR-gamma agonist, the dose of that medicine stays the same. When it is added to a sulphonylurea or insulin, the doctor may lower the dose of the sulphonylurea or insulin to reduce the risk of low blood sugar.
Kidney function decides whether a lower dose is needed, so the SmPC recommends checking it before you start and from time to time afterwards. No dose change is needed because of age or for mild to moderate liver impairment. Sitagliptin is not used in children and adolescents aged 10 to 17 because it was not effective enough, and it has not been studied in children under 10.
If you miss a dose, the leaflet says to take it as soon as you remember; if you do not remember until the next dose is due, skip the missed one and never take a double dose. Do not stop the medicine without talking to the doctor first, even when your results have reached their target.
| Kidney function (GFR) | Dose of sitagliptin in the SmPC |
|---|---|
| 45 mL/min or more | 100 mg once a day |
| 30 to under 45 mL/min | 50 mg once a day |
| 15 to under 30 mL/min | 25 mg once a day |
| Under 15 mL/min, including haemodialysis or peritoneal dialysis | 25 mg once a day, regardless of the timing of dialysis |
Who should not take Januvia and when the doctor needs to know more
The only contraindication in the SmPC is hypersensitivity to sitagliptin or to any of the other ingredients (section 4.3). The SmPC and the leaflet then describe situations that the doctor needs to know about before prescribing. Tell the doctor if any of these apply to you, and mention heart failure or any other heart condition as well, so that your treatment can be weighed as a whole.
- Pancreatitis or another disease of the pancreas, now or in the past.
- Gallstones, alcohol dependence or very high levels of triglycerides in the blood, which the leaflet names as conditions that can increase the chance of pancreatitis.
- Type 1 diabetes or diabetic ketoacidosis, which Januvia is not used to treat.
- Kidney problems, now or in the past.
- An earlier allergic reaction to sitagliptin.
- Pregnancy, a planned pregnancy or breast-feeding.
Warnings: pancreatitis, allergic reactions and blistering of the skin
Inflammation of the pancreas (acute pancreatitis) has been reported with DPP-4 inhibitors (SmPC, section 4.4). Its typical sign is severe, persistent pain in the abdomen, which may reach through to the back, with or without nausea and vomiting. If this happens, the leaflet tells you to stop taking Januvia and contact a doctor immediately. The SmPC adds that very rare cases of necrotising or haemorrhagic pancreatitis, some of them fatal, have been reported, and that Januvia is not restarted if pancreatitis is confirmed.
Serious allergic reactions, including anaphylaxis, angioedema and severe skin reactions such as Stevens-Johnson syndrome, have been reported after marketing; the SmPC notes that they began within the first three months of treatment, some after the first dose. Swelling of the face, lips, tongue or throat with difficulty breathing or swallowing, hives, blisters or peeling skin mean stopping the medicine and getting medical help without delay. In an emergency, call 112.
Bullous pemphigoid, a condition with blistering of the skin, has been reported with DPP-4 inhibitors including sitagliptin, and the SmPC says Januvia is stopped if it is suspected. Tell the doctor about any blisters. Joint pain has also been reported after marketing; if it is severe or does not settle, contact the doctor rather than waiting for it to pass.
Low blood sugar and combinations with other medicines
In the clinical studies of sitagliptin on its own, or combined with metformin or a PPAR-gamma agonist, low blood sugar occurred at rates similar to placebo (SmPC, section 4.4). The risk rises when sitagliptin is combined with a sulphonylurea or with insulin: section 4.8 reports low blood sugar in both combinations and lists it as very common with a sulphonylurea together with metformin. The doctor may then lower the dose of the other medicine.
If you take such a combination, ask the doctor or the pharmacist how to recognise a low blood sugar and what to do about it. The leaflet points out that low blood sugar can affect your ability to drive, use machines or work without a safe foothold, and that dizziness and drowsiness have been reported with sitagliptin.
Medicines that interact with sitagliptin
The SmPC considers the risk of clinically meaningful interactions low (section 4.5). In clinical studies, sitagliptin did not meaningfully change the levels of metformin, glyburide, simvastatin, rosiglitazone, warfarin or oral contraceptives. The points below are the ones the SmPC and the leaflet single out.
Because kidney function sets the dose, tell the doctor about anything that may affect it, such as a new medicine or an illness with vomiting or diarrhoea; the doctor may want your kidney function rechecked. List everything you take, including medicines bought without a prescription, food supplements and herbal products.
- Digoxin: sitagliptin raised digoxin levels slightly. No dose change is recommended, but people at risk of digoxin toxicity are monitored, and the leaflet asks you to tell the doctor if you take digoxin.
- Insulin and sulphonylureas: combined with sitagliptin they can cause low blood sugar, so their dose may be lowered.
- Potent CYP3A4 inhibitors such as ketoconazole, itraconazole, ritonavir and clarithromycin: the SmPC notes that they could change sitagliptin levels in people with severe kidney impairment or end-stage kidney disease, which has not been studied.
- Ciclosporin: it raised sitagliptin levels in a study, but the SmPC does not consider the change clinically meaningful.
Side effects listed for sitagliptin
Serious reactions reported with sitagliptin include pancreatitis and hypersensitivity reactions (SmPC, section 4.8). The table lists the effects from the placebo-controlled studies of sitagliptin on its own and from use after marketing.
Upper respiratory tract infection and inflammation of the nose and throat were among the effects reported more often with sitagliptin in the studies, whether or not the medicine caused them. Some effects were more frequent when sitagliptin was combined with other diabetes medicines, for example nausea, vomiting and wind with metformin, and swelling of the hands or legs with pioglitazone. The leaflet in your pack has the complete list. You can report a suspected side effect to the doctor or the pharmacist.
| Frequency in the SmPC | Side effects |
|---|---|
| Common (up to 1 in 10 people) | Low blood sugar (mainly with a sulphonylurea or insulin), headache |
| Uncommon (up to 1 in 100 people) | Dizziness, constipation, itching |
| Rare (up to 1 in 1,000 people) | Low platelet count (thrombocytopenia) |
| Not known (allergy and skin) | Allergic reactions including anaphylaxis and angioedema, rash, hives, inflammation of blood vessels in the skin, Stevens-Johnson syndrome and other peeling skin conditions, bullous pemphigoid |
| Not known (other) | Acute pancreatitis, interstitial lung disease, vomiting, joint pain, muscle pain, back pain, joint disease, reduced kidney function and acute kidney failure |
Cardiovascular safety in the TECOS study
In the clinical studies described in the SmPC (section 5.1), the TECOS study followed people with type 2 diabetes and established cardiovascular disease, who took sitagliptin or placebo added to their usual care. In that study, sitagliptin did not increase the risk of major cardiovascular events or of hospitalisation for heart failure compared with usual care without it. The overall rate of serious adverse events was similar in the two groups, and confirmed pancreatitis was reported slightly more often with sitagliptin than with placebo. These are results of a study, not a forecast for any one person, and they do not change the warnings above.
Pregnancy and breast-feeding
The SmPC states that Januvia should not be used during pregnancy, because there are no adequate data from pregnant women and animal studies showed reproductive toxicity at high doses (section 4.6). It should not be used while breast-feeding either: it is not known whether sitagliptin passes into human milk, and animal studies showed that it does. If you are pregnant, think you may be or plan a pregnancy, tell the doctor promptly. Diabetes treatment in pregnancy belongs with a doctor who can follow you in person.
How a request for sitagliptin is assessed
You fill in a medical questionnaire about the medicine, your health and other medicines you take, and the doctor reviews your answers in writing. Whether you already take sitagliptin or would start it, it helps to have a recent HbA1c and a recent kidney function result to hand, because kidney function sets the dose. For a first prescription your answers need to show clear indications. The general steps are described on our page about the online doctor review.
If the doctor has questions, they ask them in writing in the chat in your account, and you get an email to let you know. There is no video call, no phone call and no live chat. The doctor may ask you for test results, may recommend that you see a doctor in Malta, or may decline. For some conditions, and in some individual cases, it is advisable to see a doctor in person; the doctor may recommend this. Severe abdominal pain, a serious allergic reaction and the other warning signs above need urgent medical help, not a written review.
If the doctor issues a prescription, you receive it as a PDF by email. You print it and bring it on paper to a pharmacy in Malta together with photo identification. Your prescription is issued in the standard EU cross-border format set out in Directive 2012/52/EU. A pharmacy in Malta may dispense it; the decision rests with the pharmacist. Take the prescription to a pharmacy within six months of the date on it; a prescription for an antibiotic cannot be dispensed more than ten days after its date of issue.
What does it cost?
Two separate costs are involved. The button on this page shows the fee for the doctor's review, and the medicine itself is paid for at the pharmacy, which can tell you the price of your pack. It is not an ePrescription and does not appear in myHealth; it is outside POYC and the Government Formulary List, and you pay for the medicine at the pharmacy in full.
The fee covers the medical consultation, not the issuing of a document. If the doctor declines on medical or legal grounds, we refund the fee. If the doctor asks you for documents, you have at least 7 days to send them in and we send you a reminder; if you ask us, we agree a longer deadline. If the case still cannot be completed, we close the request, let you know and refund the fee in full.
Who reviews your request?
Your request is reviewed by Damian Wojno, a doctor registered with the Polish Medical Chamber, licence no. 3211301. The doctor is not registered with the Medical Council of Malta.
Is Januvia prescription-only in Malta?
Januvia is authorised for the whole EU through the central procedure, and its product information classifies it as a medicinal product subject to medical prescription. In the Medicines Authority register, all 51 authorised products that contain sitagliptin alone and all 39 authorised combinations are classified as prescription-only medicines (POM), so a pharmacy supplies them against a prescription.
What is the usual dose of sitagliptin?
The SmPC gives 100 mg once a day, with or without food. The dose is 50 mg once a day when kidney function (GFR) is 30 to under 45 mL/min, and 25 mg once a day below 30 mL/min, including people on dialysis. The dose that applies to you is set by the doctor from your own results.
How long does sitagliptin take to work?
In the clinical studies described in the SmPC, the effect was measured as the change in HbA1c after several months of treatment. The doctor judges your treatment in a similar way, by comparing your HbA1c with the result before you started, rather than by how you feel.
Does sitagliptin cause low blood sugar?
On its own, or with metformin or a PPAR-gamma agonist, low blood sugar occurred at rates similar to placebo in the clinical studies. The risk rises in combination with a sulphonylurea or insulin, and the doctor may then lower the dose of the other medicine.
Can sitagliptin be taken with metformin?
Adding sitagliptin to metformin is one of the uses in the SmPC, and the dose of metformin stays the same. Fixed combinations of the two exist, such as Janumet, so check the composition on your pack before adding plain sitagliptin, or you could take the same substance twice. Metformin itself is described on our page about metformin.
What are the side effects of Januvia?
Headache and low blood sugar (mainly in combination with a sulphonylurea or insulin) are listed as common; dizziness, constipation and itching as uncommon. Pancreatitis and serious allergic reactions are listed with a frequency that cannot be estimated, and they are serious: severe, persistent abdominal pain or swelling of the face, lips or throat means stopping the medicine and getting medical help.
Can I drink alcohol while taking Januvia?
The leaflet names alcohol dependence, together with gallstones and very high triglycerides, among the conditions that can increase the chance of pancreatitis. Tell the doctor honestly how much you drink, and discuss what is sensible for you with the doctor who manages your diabetes.
Can a pharmacy in Malta dispense a prescription from a doctor in another EU country?
A prescription from a doctor in another EU country can be dispensed in Malta (Article 81(3) of the Medicines Act, Cap. 458) if the pharmacist can confirm the doctor's licence. The decision rests with the pharmacist, who may refuse. You need the printed document and photo identification with you at the pharmacy.
- EMA: Januvia (sitagliptin), European public assessment report
- EMA: Januvia product information (summary of product characteristics, Annex II and package leaflet)
- EMA: Janumet (sitagliptin and metformin), European public assessment report
- Medicines Authority: Jidinum 100 mg film-coated tablets, sitagliptin (MA032/13603)
- Medicines Authority: prescription-only and non-prescription medicines
- Medicines Act (Cap. 458), Article 81 (legislation.mt)
- Prescription and Dispensing Requirements Rules (S.L. 458.49), rule 4 (legislation.mt)
- Commission Implementing Directive 2012/52/EU on the recognition of medical prescriptions issued in another Member State (EUR-Lex)